Last reviewed · How we verify

Metofane — Competitive Intelligence Brief

Metofane (METHOXYFLURANE) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: methoxyflurane. Area: Metabolic.

marketed methoxyflurane Glycine receptor subunit alpha-1, GABA-A receptor; anion channel Metabolic Small molecule Live · refreshed every 30 min

Target snapshot

Metofane (METHOXYFLURANE) — Abbott. Metofane works by binding to the GABA-A receptor and anion channel, enhancing the inhibitory effects of GABA to produce sedation and analgesia.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Metofane TARGET METHOXYFLURANE Abbott marketed methoxyflurane Glycine receptor subunit alpha-1, GABA-A receptor; anion channel

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (methoxyflurane class)

  1. Abbott · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Metofane — Competitive Intelligence Brief. https://druglandscape.com/ci/methoxyflurane. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: